Some pharmaceutical companies are troubled by stratospheric drug prices. Several have vowed to limit price hikes, for instance. And the powerful drug lobbying group PhRMA is at least trying to distract consumers’ attention away from price gouging by dangling shiny advertisements about their life-saving research.

But there are some companies that just don’t care. Mylan appears to be one of those.

Despite intense backlash from customers and advocates, several federal investigations, and blustering lawmakers, the company has yet to drop the soaring price of its epinephrine auto-injectors, EpiPen, as The New York Times pointed out this weekend. The paper sat down with 10 former high-ranking executives and Mylan’s current CEO Heather Bresch to try to understand their perspective.

According to the former employees, who requested anonymity citing nondisclosure agreements and fears of retaliation, Mylan expected outrage over its price hiking ways and planned to simply ignore it. In fact, the former executives revealed that after employees repeatedly warned about the potential for public counterblasts, the company’s chairman, Robert Coury was unmoved.

His response was summarized in this charming passage:

Mr. Coury replied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same. And regulators at the Food and Drug Administration? They, too, deserved a round of anatomically challenging self-fulfillment.

Coury, who received around $160 million in compensation last year from Mylan , declined to discuss the matter. But Bresch defended Mylan’s culture and price increases to the Times. She again deflected blame for the high prices onto the country’s complicated and inefficient healthcare system. She also vaunted Mylan’s generic version of the EpiPen, which the company released after the backlash began. A generic two-pack costs around $300 , down from the brand-name version’s $600 price tag. Before Mylan purchased the devices in 2007, a two-pack went for around $100.

Mylan made $1.1 billion in revenue per year from EpiPen sales (though that may be decreasing with the introduction of new competition, including CVS’s generic auto-injector). And the company’s executives have the highest salaries in the business.

Though Mylan may be an extreme outlier in the business, others are continuing on with price increases amid the public furor. A financial report from Friday indicated that Pfizer Inc. has ratcheted up the price of nearly a hundred drugs by an average of 20 percent so far this year, Reuters noted

Still, others are heeding consumers’ outrage. French drugmaker Sanofi pledged that it wouldn’t increase drug prices beyond the rate of healthcare inflation. And AbbVie, Allergan, and Novo Nordisk have vowed to keep price increases in the single digits per year.